“O.itemList.length” “- this.config.text.ariaShown
“This.config.text.ariaFermé”
German Health Minister Jens Spahn said he was skeptical of Russia’s claim that he had developed the “world’s first vaccine” against coronavirus.
Russian President Vladimir Putin said on state television on Tuesday (August 11) that Russia had registered a coronavirus vaccine, adding: “I know it works effectively, solid bureaucracy immunity.”
Putin said one of his daughters had already been vaccinated and had developed a higher temperature after each dose, but “now it feels good.”
Speaking to German public radio (DLF), Spahn under pressure that being the first to receive a vaccine was not important, but under pressure on the importance of creating a well-tested, shown vaccine that can be used reliably in millions or even billions of other people. by conducting studies and publishing the effects.
“The challenge is that we know very little because the Russian government is very transparent,” Spahn said. “At least for now, we know that there have been no phase 3 studies, i.e. large-scale clinical trials with thousands of control subjects.”
READ ALSO: BioNTech quarterly loss as COVID-19 vaccine trials progress
Spahn warned that it may be harmful to start vaccinating others too soon, because if it doesn’t work out, it can end other people’s confidence in vaccination.
“That’s why I’m very skeptical about what’s in Russia,” he said. “I would be pleased if we had a first smart vaccine, but based on what we know, and that is the fundamental problem, our Russian colleagues tell us very little, it has not been adequately tested.
The World Health Organization said Tuesday that it had contacted the Russian government about the appropriate foreign criteria for testing its vaccine.
Svetlana Zavidova, director of the Association of Clinical Trial Organizations, described the Russian ad as “a Pandora’s box.”
“Why do all corporations stick to regulations, but not Russian ones? Clinical trial conduct regulations are written in the blood. They will be raped,” Zavidova told Bloomberg.
Several biotech and pharmaceutical corporations have introduced phase 3 clinical trials of their candidate vaccines, meaning that they are being controlled in tens of thousands of people elsewhere. This is the final verification before the regulatory approval stage.
READ ALSO: Russian coronavirus vaccine has ‘rather few details’ and an unworthy blow can cause ‘collateral damage’
German company BioNTech (BNTX), in partnership with US pharmaceutical giant Pfizer (PFE), announced last July that it would begin testing its messenger RNA vaccine (mRNA) on nearly another 30,000 people at 120 sites worldwide.
The US company Moderna also last month announced its trials of complex mRNA vaccines on 30,000 volunteers across the United States.
Unlike classic vaccines, which work by introducing low or inactivated doses of a virus or bacteria within the framework for the immune formula to produce antibodies, a messenger RNA vaccine (ribonucleic acid) acts by transmitting a genetic code to cells that tells them to produce a protein. , which in turn activates the immune formula.